<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006056</url>
  </required_header>
  <id_info>
    <org_study_id>199/15106</org_study_id>
    <secondary_id>UMN-MT-1997-08</secondary_id>
    <secondary_id>UMN-MT-9708</secondary_id>
    <nct_id>NCT00006056</nct_id>
  </id_info>
  <brief_title>Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fairview University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Office of Rare Diseases (ORD)</source>
  <brief_summary>
    <textblock>
      OBJECTIVES: I. Determine the efficacy of unrelated donor hematopoietic stem cell&#xD;
      transplantation in the treatment of patients with life threatening hemophagocytic disorders.&#xD;
&#xD;
      II. Determine the rate of disease free survival, incidence of graft failure, and incidence of&#xD;
      graft versus host disease in these patients after undergoing this treatment regimen.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: Patients receive oral busulfan twice a day on days -9 to -6;&#xD;
      cyclophosphamide IV over 1 hour on days -5 to -2; etoposide IV over 4 hours on days -5 to -3;&#xD;
      and anti-thymocyte globulin IV twice a day on days -2 and -1 and days 1 and 2. Patients&#xD;
      undergo allogeneic hematopoietic stem cell transplantation on day 0. Filgrastim (G-CSF) is&#xD;
      administered subcutaneously beginning on day 1 and continuing until blood counts recover.&#xD;
      Patients receive graft versus host disease prophylaxis with methotrexate IV on days 1, 3, 6,&#xD;
      and 11 and cyclosporine IV over 1-4 hours (orally once the patients resumes eating) every 12&#xD;
      hours (every 8 hours for pediatric patients) starting on or prior to day -3 and continuing up&#xD;
      to 1 year.&#xD;
&#xD;
      Patients are followed at days 28 and 100, at 6 months and 1 year, and then annually for 5&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2000</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>40</enrollment>
  <condition>Chediak-Higashi Syndrome</condition>
  <condition>Graft Versus Host Disease</condition>
  <condition>X-Linked Lymphoproliferative Syndrome</condition>
  <condition>Familial Erythrophagocytic Lymphohistiocytosis</condition>
  <condition>Hemophagocytic Lymphohistiocytosis</condition>
  <condition>Virus-Associated Hemophagocytic Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic hematopoietic stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics--&#xD;
&#xD;
        Patients diagnosed with any of the following active but stable, or nonactive/quiescent,&#xD;
        hemophagocytic disorders:&#xD;
&#xD;
          -  Hemophagocytic lymphohistiocytosis (HLH)&#xD;
&#xD;
          -  Fever greater than 38.5 degrees Celsius&#xD;
&#xD;
          -  Splenomegaly (greater than 3 cm below costal margin)&#xD;
&#xD;
          -  Hemophagocytosis in bone marrow or spleen or lymph nodes&#xD;
&#xD;
          -  Disease may be confirmed by positive family history&#xD;
&#xD;
          -  No evidence of malignancy&#xD;
&#xD;
          -  Hypertriglyceridemia and/or hypofibrinogenemia&#xD;
&#xD;
          -  Fasting triglycerides at least 2.0 mmol/L or at least 3 standard deviations above&#xD;
             normal for age&#xD;
&#xD;
          -  Fibrinogen no greater than 1.5 g/L or no greater than 3 standard deviations above&#xD;
             normal&#xD;
&#xD;
          -  Cytopenia (affecting at least 2 of 3 lineages in the peripheral blood)&#xD;
&#xD;
          -  Hemoglobin less than 9.0 g/L&#xD;
&#xD;
          -  Platelet count less than 100,000/mm3&#xD;
&#xD;
        X-linked lymphoproliferative disorder (XLP)&#xD;
&#xD;
        Two or more maternally related males manifesting at least one of the following XLP&#xD;
        phenotypes:&#xD;
&#xD;
          -  Fulminant infectious mononucleosis&#xD;
&#xD;
          -  Dysgammaglobulinemia&#xD;
&#xD;
          -  Malignant lymphoma/lymphoproliferative disorder&#xD;
&#xD;
          -  Aplastic anemia&#xD;
&#xD;
          -  Lymphoid granulomatosis/vasculitis OR&#xD;
&#xD;
          -  A maternally related male in an established XLP kindred who has strong genetic (RFLP)&#xD;
             linkage to the XLP locus&#xD;
&#xD;
        Chediak-Higashi syndrome&#xD;
&#xD;
        Partial oculocutaneous albinism (hair, skin, eyes)&#xD;
&#xD;
        Frequent bacterial infections&#xD;
&#xD;
        Large peroxidase positive granules in leukocytes of peripheral blood or bone marrow&#xD;
&#xD;
        Positive family history or parental consanguinity is supportive of the diagnosis&#xD;
&#xD;
        May not have entered accelerated phase as defined by any of the following:&#xD;
&#xD;
          -  Lymphadenopathy&#xD;
&#xD;
          -  Pancytopenia&#xD;
&#xD;
          -  Histiocytes with hemophagocytosis in bone marrow, lymph nodes, liver, or spleen&#xD;
&#xD;
        Viral associated hemophagocytic syndrome (VAHS)&#xD;
&#xD;
        Relapsed after prior therapy or supportive care&#xD;
&#xD;
        Diagnostic criteria as for HLH&#xD;
&#xD;
        No hemophagocytic disorders secondary to underlying malignancy&#xD;
&#xD;
        Patients 35 years of age and under must have a hematopoietic stem cell donor that is one of&#xD;
        the following:&#xD;
&#xD;
          -  HLA A and B identical OR&#xD;
&#xD;
          -  Single HLA A or B serologic mismatch with DRB1 identity OR&#xD;
&#xD;
          -  HLA A or B serologic identity with a single DRB1 mismatch&#xD;
&#xD;
        Patients 36 to 55 years of age must have a hematopoietic stem cell donor that is one of the&#xD;
        following:&#xD;
&#xD;
          -  HLA A and B and HLA DRB1 identical OR&#xD;
&#xD;
          -  Single HLA A or B serologic mismatch with DRB1 identity&#xD;
&#xD;
        Patients receiving umbilical cord blood must have an unrelated donor with no more than two&#xD;
        antigen HLA A, B, or DRB1 mismatches&#xD;
&#xD;
        --Patient Characteristics--&#xD;
&#xD;
        Performance status: Karnofsky 70-100% OR Age less than 16 years: Lansky 50-100%&#xD;
&#xD;
        Life expectancy: Not severly limited by another disease&#xD;
&#xD;
        Hepatic: SGOT less than 3 times normal Bilirubin less than 2.5 mg/dL&#xD;
&#xD;
        Renal: Creatinine normal OR Creatinine clearance or glomerular filtration rate greater than&#xD;
        50% normal&#xD;
&#xD;
        Cardiovascular: If symptomatic, ventricular ejection fraction must be greater than 40% and&#xD;
        must improve with exercise OR Shortening fraction normal on echocardiogram&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  If symptomatic, DLCO greater than 45% predicted (corrected for hemoglobin)&#xD;
&#xD;
          -  In children unable to perform pulmonary function testing, oxygen saturation must be&#xD;
             greater than 95%&#xD;
&#xD;
        Other: HIV negative No significant active infections&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>0 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>K. Scott Baker</last_name>
    <role>Study Chair</role>
    <affiliation>Fairview University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fairview University Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2003</verification_date>
  <study_first_submitted>July 5, 2000</study_first_submitted>
  <study_first_submitted_qc>July 5, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2000</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Chediak-Higashi syndrome</keyword>
  <keyword>X-linked lymphoproliferative syndrome</keyword>
  <keyword>disease-related problem/condition</keyword>
  <keyword>familial erythrophagocytic lymphohistiocytosis</keyword>
  <keyword>genetic diseases and dysmorphic syndromes</keyword>
  <keyword>graft versus host disease</keyword>
  <keyword>hematologic disorders</keyword>
  <keyword>hemophagocytic lymphohistiocytosis</keyword>
  <keyword>histiocytosis</keyword>
  <keyword>immunologic disorders and infectious disorders</keyword>
  <keyword>primary immunodeficiency disease</keyword>
  <keyword>rare disease</keyword>
  <keyword>virus-associated hemophagocytic syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chediak-Higashi Syndrome</mesh_term>
    <mesh_term>Lymphohistiocytosis, Hemophagocytic</mesh_term>
    <mesh_term>Lymphoproliferative Disorders</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

